Get notified when QTRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Material Weakness (removed) — Previously disclosed material weaknesses in inventory valuation and Accelerator Revenue accounting have been remediated; controls now deemed effective.
- Asset Impairment (new) — Company recorded a $19.3 million impairment of in-process R&D intangible asset following termination of a diagnostics development agreement with a biopharmaceutical customer.
Quanterix remediates control weaknesses, completes Akoya deal amid core business decline
Filed May 6, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 12, 2025 · ~1 min read
Key Changes
-
high
Material weaknesses in inventory valuation and revenue recognition fully remediated; internal controls now effective as of March 31, 2026, reversing prior ineffectiveness.
Controls & Procedures verify on EDGAR → -
high
Legacy Quanterix revenue declined 19% year-over-year despite reported 20% growth; Akoya acquisition ($8.7M product, $3.7M service revenue) masked underlying weakness from reduced federal research funding.
MD&A: Revenue Performance verify on EDGAR → -
high
Submitted 510(k) application to FDA for Alzheimer's blood test (January 2026); CMS approved $897 reimbursement rate for LucentAD Complete, establishing national reference pricing.
MD&A: Regulatory Milestones verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.
Partner
Trade QTRX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify